Last 12 months
Inside the activity.
0 purchase rows · 27 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 3 |
| Jan 2026 | 0 | 7 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 10 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 2 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 15, 2018 Filed Jun 16, 2018 01:41 UTC |
KASINGER JAMES R.General Counsel and Secretary
|
GrantStock Option (Right to Buy) · Derivative | 32,000 | $0.00 Strike: $59.31 | $0.00 |
DisclosureSEC source: 0000899243-18-016879 · doc4.xml · derivative · entry 1 KASINGER JAMES R. · CIK 0001708172 · General Counsel and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 Underlying: Common Shares · 32,000 shares Expires 2028-06-15 F1 · derivative.exercise_date: This option was granted on June 15, 2018 with respect to 32,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments. Read SEC document |
| June 15, 2018 Filed Jun 16, 2018 01:40 UTC |
Bolzon Bradley J PhDDirector
|
GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $59.31 | $0.00 |
DisclosureSEC source: 0000899243-18-016878 · doc4.xml · derivative · entry 1 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 30,000 Underlying: Common Shares · 30,000 shares Expires 2028-06-15 F2 · shares: One-half of the securities acquired as reported in column 5 were granted to the Reporting Person and one-half were granted to Thomas Woiwode, each grant as compensation for services on the Issuer's board of directors. One-half of the securities held after the reported transaction, as reported in column 9, are held by the Reporting Person and one-half of the reported securities are held by Mr. Woiwode. Each of the Reporting Person and Mr. Woiwode are managing members of Versant Venture Management, LLC and pursuant to agreements with Versant Venture Management, LLC, the Reporting Person and Mr. Woiwode are deemed to hold these securities for the benefit of Versant Venture Management, LLC. Accordingly, Versant Venture Management, LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficial own the securities through his interest in Versant Venture Management, LLC. F3 · shares: (Continued from Footnote #2) The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. F1 · derivative.exercise_date: This option was granted on June 15, 2018 with 100% of the shares vesting in 12 equal monthly installments beginning on May 30, 2018. F2 · derivative.underlying_shares: One-half of the securities acquired as reported in column 5 were granted to the Reporting Person and one-half were granted to Thomas Woiwode, each grant as compensation for services on the Issuer's board of directors. One-half of the securities held after the reported transaction, as reported in column 9, are held by the Reporting Person and one-half of the reported securities are held by Mr. Woiwode. Each of the Reporting Person and Mr. Woiwode are managing members of Versant Venture Management, LLC and pursuant to agreements with Versant Venture Management, LLC, the Reporting Person and Mr. Woiwode are deemed to hold these securities for the benefit of Versant Venture Management, LLC. Accordingly, Versant Venture Management, LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficial own the securities through his interest in Versant Venture Management, LLC. F3 · derivative.underlying_shares: (Continued from Footnote #2) The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. F2 · balance_after: One-half of the securities acquired as reported in column 5 were granted to the Reporting Person and one-half were granted to Thomas Woiwode, each grant as compensation for services on the Issuer's board of directors. One-half of the securities held after the reported transaction, as reported in column 9, are held by the Reporting Person and one-half of the reported securities are held by Mr. Woiwode. Each of the Reporting Person and Mr. Woiwode are managing members of Versant Venture Management, LLC and pursuant to agreements with Versant Venture Management, LLC, the Reporting Person and Mr. Woiwode are deemed to hold these securities for the benefit of Versant Venture Management, LLC. Accordingly, Versant Venture Management, LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficial own the securities through his interest in Versant Venture Management, LLC. F3 · balance_after: (Continued from Footnote #2) The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. F2 · ownership.nature: One-half of the securities acquired as reported in column 5 were granted to the Reporting Person and one-half were granted to Thomas Woiwode, each grant as compensation for services on the Issuer's board of directors. One-half of the securities held after the reported transaction, as reported in column 9, are held by the Reporting Person and one-half of the reported securities are held by Mr. Woiwode. Each of the Reporting Person and Mr. Woiwode are managing members of Versant Venture Management, LLC and pursuant to agreements with Versant Venture Management, LLC, the Reporting Person and Mr. Woiwode are deemed to hold these securities for the benefit of Versant Venture Management, LLC. Accordingly, Versant Venture Management, LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficial own the securities through his interest in Versant Venture Management, LLC. F3 · ownership.nature: (Continued from Footnote #2) The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 15, 2018 Filed Jun 16, 2018 01:39 UTC |
Woiwode ThomasDirector
|
GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $59.31 | $0.00 |
DisclosureSEC source: 0000899243-18-016876 · doc4.xml · derivative · entry 1 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2028-06-15 F2 · shares: One-half of the securities acquired as reported in column 5 were granted to the Reporting Person and one-half were granted to Bradley Bolzon, each grant as compensation for services on the Issuer's board of directors. One-half of the securities held after the reported transaction, as reported in column 9, are held by the Reporting Person and one-half of the reported securities are held by Mr. Bolzon. Each of the Reporting Person and Mr. Bolzon are managing members of Versant Venture Management, LLC and pursuant to agreements with Versant Venture Management, LLC, the Reporting Person and Mr. Bolzon are deemed to hold these securities for the benefit of Versant Venture Management, LLC. Accordingly, Versant Venture Management, LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficial own the securities through his interest in Versant Venture Management, LLC. F3 · shares: (Continued from Footnote 2) The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. F1 · derivative.exercise_date: This option was granted on June 15, 2018 100% of the shares vesting in 12 equal monthly installments beginning on May 30, 2018. F2 · derivative.underlying_shares: One-half of the securities acquired as reported in column 5 were granted to the Reporting Person and one-half were granted to Bradley Bolzon, each grant as compensation for services on the Issuer's board of directors. One-half of the securities held after the reported transaction, as reported in column 9, are held by the Reporting Person and one-half of the reported securities are held by Mr. Bolzon. Each of the Reporting Person and Mr. Bolzon are managing members of Versant Venture Management, LLC and pursuant to agreements with Versant Venture Management, LLC, the Reporting Person and Mr. Bolzon are deemed to hold these securities for the benefit of Versant Venture Management, LLC. Accordingly, Versant Venture Management, LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficial own the securities through his interest in Versant Venture Management, LLC. F3 · derivative.underlying_shares: (Continued from Footnote 2) The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. F2 · balance_after: One-half of the securities acquired as reported in column 5 were granted to the Reporting Person and one-half were granted to Bradley Bolzon, each grant as compensation for services on the Issuer's board of directors. One-half of the securities held after the reported transaction, as reported in column 9, are held by the Reporting Person and one-half of the reported securities are held by Mr. Bolzon. Each of the Reporting Person and Mr. Bolzon are managing members of Versant Venture Management, LLC and pursuant to agreements with Versant Venture Management, LLC, the Reporting Person and Mr. Bolzon are deemed to hold these securities for the benefit of Versant Venture Management, LLC. Accordingly, Versant Venture Management, LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficial own the securities through his interest in Versant Venture Management, LLC. F3 · balance_after: (Continued from Footnote 2) The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. F2 · ownership.nature: One-half of the securities acquired as reported in column 5 were granted to the Reporting Person and one-half were granted to Bradley Bolzon, each grant as compensation for services on the Issuer's board of directors. One-half of the securities held after the reported transaction, as reported in column 9, are held by the Reporting Person and one-half of the reported securities are held by Mr. Bolzon. Each of the Reporting Person and Mr. Bolzon are managing members of Versant Venture Management, LLC and pursuant to agreements with Versant Venture Management, LLC, the Reporting Person and Mr. Bolzon are deemed to hold these securities for the benefit of Versant Venture Management, LLC. Accordingly, Versant Venture Management, LLC may be deemed to be the indirect beneficial owner of these securities, and the Reporting Person may be deemed to indirectly beneficial own the securities through his interest in Versant Venture Management, LLC. F3 · ownership.nature: (Continued from Footnote 2) The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein. Read SEC document |
| June 15, 2018 Filed Jun 16, 2018 01:38 UTC |
Ho Tony WSee Remarks
|
GrantStock Option (Right to Buy) · Derivative | 43,000 | $0.00 Strike: $59.31 | $0.00 |
DisclosureSEC source: 0000899243-18-016875 · doc4.xml · derivative · entry 1 Ho Tony W · CIK 0001713637 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,000 Underlying: Common Shares · 43,000 shares Expires 2028-06-15 F1 · derivative.exercise_date: This option was granted on June 15, 2018 with respect to 43,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments. Read SEC document |
| June 15, 2018 Filed Jun 16, 2018 01:37 UTC |
TOMSICEK MICHAEL JOHNChief Financial Officer
|
GrantStock Option (Right to Buy) · Derivative | 20,760 | $0.00 Strike: $59.31 | $0.00 |
DisclosureSEC source: 0000899243-18-016872 · doc4.xml · derivative · entry 1 TOMSICEK MICHAEL JOHN · CIK 0001570392 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,760 Underlying: Common Shares · 20,760 shares Expires 2028-06-15 F1 · derivative.exercise_date: This option was granted on June 15, 2018 with respect to 20,760 Common Shares with 100% of the shares vesting in 48 equal monthly installments. Read SEC document |
| June 15, 2018 Filed Jun 16, 2018 01:36 UTC |
Kulkarni SamarthDirector · Chief Executive Officer
|
GrantStock Option (Right to Buy) · Derivative | 109,000 | $0.00 Strike: $59.31 | $0.00 |
DisclosureSEC source: 0000899243-18-016871 · doc4.xml · derivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,000 Underlying: Common Shares · 109,000 shares Expires 2028-06-15 F1 · derivative.exercise_date: This option was granted on June 15, 2018 with respect to 109,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments. Read SEC document |
| June 15, 2018 Filed Jun 16, 2018 01:35 UTC |
CAGNONI PABLO JDirector
|
GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $59.31 | $0.00 |
DisclosureSEC source: 0000899243-18-016868 · doc4.xml · derivative · entry 1 CAGNONI PABLO J · CIK 0001205703 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Shares · 15,000 shares Expires 2018-06-15 F1 · derivative.exercise_date: This option was granted on June 15, 2018 with respect to 15,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on May 30, 2018. Read SEC document |
| June 15, 2018 Filed Jun 18, 2018 20:21 UTC |
EMSTER KURT VONDirector
|
GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $59.31 | $0.00 |
DisclosureSEC source: 0000905718-18-000569 · crisprfm4_jun152018.xml · derivative · entry 1 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Shares · 15,000 shares Expires 2028-06-15 F1 · derivative.exercise_date: This option was granted on June 15, 2018 with respect to 15,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on May 30, 2018. Read SEC document |
| June 15, 2018 Filed Jun 19, 2018 20:55 UTC |
George SimeonDirector
|
GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $59.31 | $0.00 |
DisclosureSEC source: 0000899243-18-017194 · doc4.xml · derivative · entry 1 George Simeon · CIK 0001595117 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Shares · 15,000 shares Expires 2028-06-15 F1 · derivative.exercise_date: This option was granted on June 15, 2018 with respect to 15,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on May 30, 2018. The stock option was granted to the Reporting Person as director's compensation. As a Vice President of S.R. One, Limited and an employee of GlaxoSmithKline LLC, the Reporting Person is obligated to transfer any shares issued under the stock option to S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 20:36 UTC |
EMSTER KURT VONDirector
|
OtherWarrant (right to buy) · Derivative | 2,000 | $0.00 Strike: $5.75 | $0.00 |
DisclosureSEC source: 0000905718-18-000554 · crispr-fm4_jun42018.xml · derivative · entry 5 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005 Disclosed balance after: 0 Underlying: Common Stock · 2,000 shares Expires 2018-09-30 Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 20:36 UTC |
EMSTER KURT VONDirector
|
SaleCommon Stock | 920 | $12.51 | $11,509.20 |
DisclosureSEC source: 0000905718-18-000554 · crispr-fm4_jun42018.xml · nonDerivative · entry 2 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005 Disclosed balance after: 18,316 F1 · kind: On June 5, 2018, Kurt von Emster (the "Reporting Person") on behalf of the Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005, exercised a warrant to purchase 2,000 shares of CymaBay Therapeutics, Inc. ("CBAY") common stock for $5.75 per share. The Reporting Person paid the exercise price on a cashless basis, resulting in CBAY's withholding of 920 of the warrant shares to pay the exercise price and issuing to the Reporting Person the remaining 1,080 shares. CBAY also paid $9.47 to the Reporting Person in lieu of a fractional share. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 20:36 UTC |
EMSTER KURT VONDirector
|
OtherCommon Stock | 2,000 | $5.75 | $11,500.00 |
DisclosureSEC source: 0000905718-18-000554 · crispr-fm4_jun42018.xml · nonDerivative · entry 1 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005 Disclosed balance after: 19,236 Read SEC document |
| June 04, 2018 Filed Jun 6, 2018 00:20 UTC |
Kulkarni SamarthDirector · Chief Executive Officer
|
Tax withholdingCommon Shares | 741 | $67.13 | $49,743.33 |
DisclosureSEC source: 0000899243-18-015158 · doc4.xml · nonDerivative · entry 4 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,819 Read SEC document |
| June 01, 2018 Filed Jun 6, 2018 00:20 UTC |
Kulkarni SamarthDirector · Chief Executive Officer
|
Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0000899243-18-015158 · doc4.xml · derivative · entry 5 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,558 Underlying: Common Shares · 15,000 shares Expires 2025-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option was granted on September 10, 2015 with respect to 321,712 Common Shares with 120,640 of the shares vested on August 1, 2016, the first anniversary of employment commencement, and the remainder vest in equal 36 monthly installments thereafter. Read SEC document |
| June 01, 2018 Filed Jun 6, 2018 00:20 UTC |
Kulkarni SamarthDirector · Chief Executive Officer
|
SaleCommon Shares | 10,400 | $70.28 | $730,912.00 |
DisclosureSEC source: 0000899243-18-015158 · doc4.xml · nonDerivative · entry 3 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 148,560 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $70.00 to $70.82 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. Read SEC document |
| June 01, 2018 Filed Jun 6, 2018 00:20 UTC |
Kulkarni SamarthDirector · Chief Executive Officer
|
SaleCommon Shares | 4,600 | $67.28 | $309,488.00 |
DisclosureSEC source: 0000899243-18-015158 · doc4.xml · nonDerivative · entry 2 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,960 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.01 to $67.60 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. Read SEC document |
| June 01, 2018 Filed Jun 6, 2018 00:20 UTC |
Kulkarni SamarthDirector · Chief Executive Officer
|
Exercise / conversionCommon Shares | 15,000 | $1.81 | $27,150.00 |
DisclosureSEC source: 0000899243-18-015158 · doc4.xml · nonDerivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,560 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 17, 2018 Filed May 21, 2018 20:54 UTC |
Novak RodgerDirector · President
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 39,760 | $0.00 Strike: $14.00 | $0.00 |
DisclosureSEC source: 0000899243-18-013577 · doc4.xml · derivative · entry 5 Novak Rodger · CIK 0001682017 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,240 Underlying: Common Stock · 39,760 shares Expires 2016-10-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option was granted on October 18, 2016 with respect to 200,000 Common Shares with 100% of the shares vesting in 48 equal monthly installments beginning October 31, 2016. Read SEC document |
| May 17, 2018 Filed May 21, 2018 20:54 UTC |
Novak RodgerDirector · President
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 35,240 | $0.00 Strike: $1.81 | $0.00 |
DisclosureSEC source: 0000899243-18-013577 · doc4.xml · derivative · entry 4 Novak Rodger · CIK 0001682017 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,586 Underlying: Common Stock · 35,240 shares Expires 2025-09-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option was granted on September 10, 2015 with respect to 268,093 Common Shares with 94,950 shares immediately vested on the grant date and the remaining 173,143 shares vest in 31equal monthly installments thereafter. Read SEC document |
| May 17, 2018 Filed May 21, 2018 20:54 UTC |
Novak RodgerDirector · President
|
SaleCommon Shares | 75,000 | $60.00 | $4,500,000.00 |
DisclosureSEC source: 0000899243-18-013577 · doc4.xml · nonDerivative · entry 3 Novak Rodger · CIK 0001682017 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,148,007 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. Read SEC document |
| May 17, 2018 Filed May 21, 2018 20:54 UTC |
Novak RodgerDirector · President
|
Exercise / conversionCommon Shares | 39,760 | $14.00 | $556,640.00 |
DisclosureSEC source: 0000899243-18-013577 · doc4.xml · nonDerivative · entry 2 Novak Rodger · CIK 0001682017 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,223,007 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 17, 2018 Filed May 21, 2018 20:54 UTC |
Novak RodgerDirector · President
|
Exercise / conversionCommon Shares | 35,240 | $1.81 | $63,784.40 |
DisclosureSEC source: 0000899243-18-013577 · doc4.xml · nonDerivative · entry 1 Novak Rodger · CIK 0001682017 · Director · President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,183,247 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2018 Filed May 17, 2018 21:15 UTC |
Bolzon Bradley J PhDDirector
|
SaleCommon Shares | 1,000 | $58.73 | $58,730.00 |
DisclosureSEC source: 0000899243-18-013244 · doc4.xml · nonDerivative · entry 2 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 640,014 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.585 to $58.785 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F2 · ownership.nature: These securities are held of record by Versant Venture Management, LLC ("VVM LLC"). The Reporting Person is a managing member of VVM LLC and may be deemed to indirectly beneficially own the shares through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein. Read SEC document |
| May 15, 2018 Filed May 17, 2018 21:15 UTC |
Bolzon Bradley J PhDDirector
|
SaleCommon Shares | 43,000 | $57.97 | $2,492,710.00 |
DisclosureSEC source: 0000899243-18-013244 · doc4.xml · nonDerivative · entry 1 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 641,014 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.54 to $58.50 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F2 · ownership.nature: These securities are held of record by Versant Venture Management, LLC ("VVM LLC"). The Reporting Person is a managing member of VVM LLC and may be deemed to indirectly beneficially own the shares through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein. Read SEC document |
| May 15, 2018 Filed May 17, 2018 21:11 UTC |
Woiwode ThomasDirector
|
SaleCommon Shares | 1,000 | $58.73 | $58,730.00 |
DisclosureSEC source: 0000899243-18-013239 · doc4.xml · nonDerivative · entry 2 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 640,014 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.585 to $58.785 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F2 · ownership.nature: These securities are held of record by Versant Venture Management, LLC ("VVM LLC"). The Reporting Person is a managing member of VVM LLC and may be deemed to indirectly beneficially own the shares through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein. Read SEC document |
| May 15, 2018 Filed May 17, 2018 21:11 UTC |
Woiwode ThomasDirector
|
SaleCommon Shares | 43,000 | $57.97 | $2,492,710.00 |
DisclosureSEC source: 0000899243-18-013239 · doc4.xml · nonDerivative · entry 1 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 641,014 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.54 to $58.50 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F2 · ownership.nature: These securities are held of record by Versant Venture Management, LLC ("VVM LLC"). The Reporting Person is a managing member of VVM LLC and may be deemed to indirectly beneficially own the shares through his interest in VVM LLC. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein. Read SEC document |
| May 14, 2018 Filed May 16, 2018 00:04 UTC |
EMSTER KURT VONDirector
|
SaleCommon Shares | 8,900 | $52.20 | $464,539.95 |
DisclosureSEC source: 0000905718-18-000518 · crispr-fm4_may112018.xml · nonDerivative · entry 9 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,237,202 F1 · kind: Kurt von Emster's (the "Reporting Person") pecuniary interest in Abingworth Bioventures VI LP's ("ABV VI") May 11, 2018 and May 14, 2018 sales of common stock of CRISPR Therapeutics AG ("Issuer") reported herein were matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of Reporting Person's pecuniary interest in Abingworth BioEquities Master Fund Limited's ("ABE") January 5, 2018 purchase of 65,934 shares of common stock of Issuer at a price of $22.75 per share. The Reporting Person has agreed to pay to Issuer the full amount of the Reporting Person's pecuniary interest in the profit realized in connection with the short-swing transactions, less transaction costs (rounded to the nearest dollar). F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.00 to $52.37 per share, inclusive. F13 · price: The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F2 · ownership.nature: Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI. F3 · ownership.nature: From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI and ABE to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| May 14, 2018 Filed May 16, 2018 00:04 UTC |
EMSTER KURT VONDirector
|
SaleCommon Shares | 20,881 | $52.93 | $1,105,312.77 |
DisclosureSEC source: 0000905718-18-000518 · crispr-fm4_may112018.xml · nonDerivative · entry 8 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,246,102 F1 · kind: Kurt von Emster's (the "Reporting Person") pecuniary interest in Abingworth Bioventures VI LP's ("ABV VI") May 11, 2018 and May 14, 2018 sales of common stock of CRISPR Therapeutics AG ("Issuer") reported herein were matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of Reporting Person's pecuniary interest in Abingworth BioEquities Master Fund Limited's ("ABE") January 5, 2018 purchase of 65,934 shares of common stock of Issuer at a price of $22.75 per share. The Reporting Person has agreed to pay to Issuer the full amount of the Reporting Person's pecuniary interest in the profit realized in connection with the short-swing transactions, less transaction costs (rounded to the nearest dollar). F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.38 to $53.37 per share, inclusive. F13 · price: The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F2 · ownership.nature: Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI. F3 · ownership.nature: From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI and ABE to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| May 14, 2018 Filed May 16, 2018 00:04 UTC |
EMSTER KURT VONDirector
|
SaleCommon Shares | 53,927 | $53.86 | $2,904,578.33 |
DisclosureSEC source: 0000905718-18-000518 · crispr-fm4_may112018.xml · nonDerivative · entry 7 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,266,983 F1 · kind: Kurt von Emster's (the "Reporting Person") pecuniary interest in Abingworth Bioventures VI LP's ("ABV VI") May 11, 2018 and May 14, 2018 sales of common stock of CRISPR Therapeutics AG ("Issuer") reported herein were matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of Reporting Person's pecuniary interest in Abingworth BioEquities Master Fund Limited's ("ABE") January 5, 2018 purchase of 65,934 shares of common stock of Issuer at a price of $22.75 per share. The Reporting Person has agreed to pay to Issuer the full amount of the Reporting Person's pecuniary interest in the profit realized in connection with the short-swing transactions, less transaction costs (rounded to the nearest dollar). F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.38 to $54.37 per share, inclusive. F13 · price: The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F2 · ownership.nature: Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI. F3 · ownership.nature: From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI and ABE to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| May 14, 2018 Filed May 16, 2018 00:04 UTC |
EMSTER KURT VONDirector
|
SaleCommon Shares | 126,901 | $54.99 | $6,978,273.30 |
DisclosureSEC source: 0000905718-18-000518 · crispr-fm4_may112018.xml · nonDerivative · entry 6 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,320,910 F1 · kind: Kurt von Emster's (the "Reporting Person") pecuniary interest in Abingworth Bioventures VI LP's ("ABV VI") May 11, 2018 and May 14, 2018 sales of common stock of CRISPR Therapeutics AG ("Issuer") reported herein were matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of Reporting Person's pecuniary interest in Abingworth BioEquities Master Fund Limited's ("ABE") January 5, 2018 purchase of 65,934 shares of common stock of Issuer at a price of $22.75 per share. The Reporting Person has agreed to pay to Issuer the full amount of the Reporting Person's pecuniary interest in the profit realized in connection with the short-swing transactions, less transaction costs (rounded to the nearest dollar). F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.39 to $55.37 per share, inclusive. F13 · price: The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F2 · ownership.nature: Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI. F3 · ownership.nature: From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI and ABE to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| May 14, 2018 Filed May 16, 2018 00:04 UTC |
EMSTER KURT VONDirector
|
SaleCommon Shares | 73,144 | $55.72 | $4,075,722.65 |
DisclosureSEC source: 0000905718-18-000518 · crispr-fm4_may112018.xml · nonDerivative · entry 5 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,447,811 F1 · kind: Kurt von Emster's (the "Reporting Person") pecuniary interest in Abingworth Bioventures VI LP's ("ABV VI") May 11, 2018 and May 14, 2018 sales of common stock of CRISPR Therapeutics AG ("Issuer") reported herein were matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of Reporting Person's pecuniary interest in Abingworth BioEquities Master Fund Limited's ("ABE") January 5, 2018 purchase of 65,934 shares of common stock of Issuer at a price of $22.75 per share. The Reporting Person has agreed to pay to Issuer the full amount of the Reporting Person's pecuniary interest in the profit realized in connection with the short-swing transactions, less transaction costs (rounded to the nearest dollar). F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.37 to $56.37 per share, inclusive. F13 · price: The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F2 · ownership.nature: Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI. F3 · ownership.nature: From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI and ABE to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| May 14, 2018 Filed May 16, 2018 00:04 UTC |
EMSTER KURT VONDirector
|
SaleCommon Shares | 116,247 | $56.90 | $6,614,128.81 |
DisclosureSEC source: 0000905718-18-000518 · crispr-fm4_may112018.xml · nonDerivative · entry 4 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,520,955 F1 · kind: Kurt von Emster's (the "Reporting Person") pecuniary interest in Abingworth Bioventures VI LP's ("ABV VI") May 11, 2018 and May 14, 2018 sales of common stock of CRISPR Therapeutics AG ("Issuer") reported herein were matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of Reporting Person's pecuniary interest in Abingworth BioEquities Master Fund Limited's ("ABE") January 5, 2018 purchase of 65,934 shares of common stock of Issuer at a price of $22.75 per share. The Reporting Person has agreed to pay to Issuer the full amount of the Reporting Person's pecuniary interest in the profit realized in connection with the short-swing transactions, less transaction costs (rounded to the nearest dollar). F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.38 to $57.37 per share, inclusive. F13 · price: The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F2 · ownership.nature: Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI. F3 · ownership.nature: From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI and ABE to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| May 14, 2018 Filed May 15, 2018 20:32 UTC |
Behbahani AliDirector
|
OtherCommon Stock | 199 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-030237 · doc4.xml · nonDerivative · entry 1 Behbahani Ali · CIK 0001613867 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 199 F1 · kind: NEA Partners 15, L.P. ("NEA Partners 15") made a pro rata distribution for no consideration of an aggregate of 20,879 shares of Common Stock of the Issuer to its limited partners on May 14, 2018. The Reporting Person received 199 shares of Common Stock of the Issuer in the distribution by NEA Partners 15 on May 14, 2018. Read SEC document |
| May 11, 2018 Filed May 16, 2018 00:04 UTC |
EMSTER KURT VONDirector
|
SaleCommon Shares | 8,633 | $51.73 | $446,554.01 |
DisclosureSEC source: 0000905718-18-000518 · crispr-fm4_may112018.xml · nonDerivative · entry 3 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,637,202 F1 · kind: Kurt von Emster's (the "Reporting Person") pecuniary interest in Abingworth Bioventures VI LP's ("ABV VI") May 11, 2018 and May 14, 2018 sales of common stock of CRISPR Therapeutics AG ("Issuer") reported herein were matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of Reporting Person's pecuniary interest in Abingworth BioEquities Master Fund Limited's ("ABE") January 5, 2018 purchase of 65,934 shares of common stock of Issuer at a price of $22.75 per share. The Reporting Person has agreed to pay to Issuer the full amount of the Reporting Person's pecuniary interest in the profit realized in connection with the short-swing transactions, less transaction costs (rounded to the nearest dollar). F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.45 to $51.94 per share, inclusive. F13 · price: The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F2 · ownership.nature: Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI. F3 · ownership.nature: From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI and ABE to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| May 11, 2018 Filed May 16, 2018 00:04 UTC |
EMSTER KURT VONDirector
|
SaleCommon Shares | 127,890 | $52.46 | $6,708,610.63 |
DisclosureSEC source: 0000905718-18-000518 · crispr-fm4_may112018.xml · nonDerivative · entry 2 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,645,835 F1 · kind: Kurt von Emster's (the "Reporting Person") pecuniary interest in Abingworth Bioventures VI LP's ("ABV VI") May 11, 2018 and May 14, 2018 sales of common stock of CRISPR Therapeutics AG ("Issuer") reported herein were matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of Reporting Person's pecuniary interest in Abingworth BioEquities Master Fund Limited's ("ABE") January 5, 2018 purchase of 65,934 shares of common stock of Issuer at a price of $22.75 per share. The Reporting Person has agreed to pay to Issuer the full amount of the Reporting Person's pecuniary interest in the profit realized in connection with the short-swing transactions, less transaction costs (rounded to the nearest dollar). F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.95 to $52.94 per share, inclusive. F13 · price: The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F2 · ownership.nature: Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI. F3 · ownership.nature: From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI and ABE to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| May 11, 2018 Filed May 16, 2018 00:04 UTC |
EMSTER KURT VONDirector
|
SaleCommon Shares | 113,477 | $53.36 | $6,054,735.55 |
DisclosureSEC source: 0000905718-18-000518 · crispr-fm4_may112018.xml · nonDerivative · entry 1 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,773,725 F1 · kind: Kurt von Emster's (the "Reporting Person") pecuniary interest in Abingworth Bioventures VI LP's ("ABV VI") May 11, 2018 and May 14, 2018 sales of common stock of CRISPR Therapeutics AG ("Issuer") reported herein were matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of Reporting Person's pecuniary interest in Abingworth BioEquities Master Fund Limited's ("ABE") January 5, 2018 purchase of 65,934 shares of common stock of Issuer at a price of $22.75 per share. The Reporting Person has agreed to pay to Issuer the full amount of the Reporting Person's pecuniary interest in the profit realized in connection with the short-swing transactions, less transaction costs (rounded to the nearest dollar). F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.95 to $53.94 per share, inclusive. F13 · price: The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F2 · ownership.nature: Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI. F3 · ownership.nature: From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI and ABE to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| May 08, 2018 Filed May 9, 2018 21:15 UTC |
Woiwode ThomasDirector
|
SaleCommon Shares | 1,653 | $51.45 | $85,046.85 |
DisclosureSEC source: 0000899243-18-012101 · doc4.xml · nonDerivative · entry 9 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,629 F11 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| May 08, 2018 Filed May 9, 2018 21:14 UTC |
Bolzon Bradley J PhDDirector
|
SaleCommon Shares | 2,900 | $51.38 | $149,002.00 |
DisclosureSEC source: 0000899243-18-012100 · doc4.xml · nonDerivative · entry 10 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,745 F11 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F13 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.51 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. Read SEC document |
| May 08, 2018 Filed May 9, 2018 21:14 UTC |
Bolzon Bradley J PhDDirector
|
SaleCommon Shares | 6,341 | $50.16 | $318,064.56 |
DisclosureSEC source: 0000899243-18-012100 · doc4.xml · nonDerivative · entry 9 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,645 F11 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.66 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. Read SEC document |
| May 07, 2018 Filed May 9, 2018 21:15 UTC |
Woiwode ThomasDirector
|
SaleCommon Shares | 582 | $51.26 | $29,833.32 |
DisclosureSEC source: 0000899243-18-012101 · doc4.xml · nonDerivative · entry 8 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 90,730 F8 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Venture Capital V (Canada), L.P. ("VVC CAN"). F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.61 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F9 · ownership.nature: These securities are held of record by VVC CAN. Versant Ventures V GP-GP (Canada), Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a director of VV V CAN GP and may be deemed to indirectly beneficially own the shares through his interest in VV V CAN GP. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| May 07, 2018 Filed May 9, 2018 21:15 UTC |
Woiwode ThomasDirector
|
SaleCommon Shares | 249 | $51.26 | $12,763.74 |
DisclosureSEC source: 0000899243-18-012101 · doc4.xml · nonDerivative · entry 7 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 38,772 F6 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA"). F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.61 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F7 · ownership.nature: These securities are held of record by VOA. VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| May 07, 2018 Filed May 9, 2018 21:15 UTC |
Woiwode ThomasDirector
|
SaleCommon Shares | 225 | $51.26 | $11,533.50 |
DisclosureSEC source: 0000899243-18-012101 · doc4.xml · nonDerivative · entry 6 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 34,977 F4 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Affiliates Fund V, L.P. ("VAF V"). F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.61 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F5 · ownership.nature: These securities are held of record by VAF V. VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| May 07, 2018 Filed May 9, 2018 21:15 UTC |
Woiwode ThomasDirector
|
SaleCommon Shares | 7,645 | $51.26 | $391,882.70 |
DisclosureSEC source: 0000899243-18-012101 · doc4.xml · nonDerivative · entry 5 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,192,139 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Venture Capital V, L.P. ("VVC V"). F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.61 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F3 · ownership.nature: These securities are held of record by VVC V. Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| May 07, 2018 Filed May 9, 2018 21:15 UTC |
Woiwode ThomasDirector
|
SaleCommon Shares | 7,424 | $50.31 | $373,501.44 |
DisclosureSEC source: 0000899243-18-012101 · doc4.xml · nonDerivative · entry 4 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 91,312 F8 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Venture Capital V (Canada), L.P. ("VVC CAN"). F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.99 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F9 · ownership.nature: These securities are held of record by VVC CAN. Versant Ventures V GP-GP (Canada), Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a director of VV V CAN GP and may be deemed to indirectly beneficially own the shares through his interest in VV V CAN GP. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| May 07, 2018 Filed May 9, 2018 21:15 UTC |
Woiwode ThomasDirector
|
SaleCommon Shares | 3,172 | $50.31 | $159,583.32 |
DisclosureSEC source: 0000899243-18-012101 · doc4.xml · nonDerivative · entry 3 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 39,021 F6 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA"). F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.99 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F7 · ownership.nature: These securities are held of record by VOA. VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| May 07, 2018 Filed May 9, 2018 21:15 UTC |
Woiwode ThomasDirector
|
SaleCommon Shares | 2,862 | $50.31 | $143,987.22 |
DisclosureSEC source: 0000899243-18-012101 · doc4.xml · nonDerivative · entry 2 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 35,202 F4 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Affiliates Fund V, L.P. ("VAF V"). F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.99 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F5 · ownership.nature: These securities are held of record by VAF V. VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| May 07, 2018 Filed May 9, 2018 21:15 UTC |
Woiwode ThomasDirector
|
SaleCommon Shares | 97,550 | $50.31 | $4,907,740.50 |
DisclosureSEC source: 0000899243-18-012101 · doc4.xml · nonDerivative · entry 1 Woiwode Thomas · CIK 0001619294 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 1,199,784 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Venture Capital V, L.P. ("VVC V"). F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.00 to $50.99 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F3 · ownership.nature: These securities are held of record by VVC V. Versant Ventures V, LLC ("VV V") is the sole general partner of VVC V and may be deemed to have voting and investment power over the securities held by VVC V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| May 07, 2018 Filed May 9, 2018 21:14 UTC |
Bolzon Bradley J PhDDirector
|
SaleCommon Shares | 582 | $51.26 | $29,833.32 |
DisclosureSEC source: 0000899243-18-012100 · doc4.xml · nonDerivative · entry 8 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 90,730 F8 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Venture Capital V (Canada), L.P. ("VVC CAN"). F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.61 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F9 · ownership.nature: These securities are held of record by VVC CAN. Versant Ventures V GP-GP (Canada), Inc. ("VV V CAN GP") is the sole general partner of Versant Ventures V (Canada), L.P. ("VV V CAN") and VV V CAN is the sole general partner of VVC CAN. VV V CAN GP and VV V CAN may be deemed to have voting and investment power over the securities held by VVC CAN and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a director of VV V CAN GP and may be deemed to indirectly beneficially own the shares through his interest in VV V CAN GP. The Reporting Person disclaims beneficial ownership of these shares, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| May 07, 2018 Filed May 9, 2018 21:14 UTC |
Bolzon Bradley J PhDDirector
|
SaleCommon Shares | 249 | $51.26 | $12,763.74 |
DisclosureSEC source: 0000899243-18-012100 · doc4.xml · nonDerivative · entry 7 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 38,772 F6 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Ophthalmic Affiliates Fund I, L.P. ("VOA"). F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.61 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F7 · ownership.nature: These securities are held of record by VOA. VV V is the sole general partner of VOA and may be deemed to have voting and investment power over the securities held by VOA and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
| May 07, 2018 Filed May 9, 2018 21:14 UTC |
Bolzon Bradley J PhDDirector
|
SaleCommon Shares | 225 | $51.26 | $11,533.50 |
DisclosureSEC source: 0000899243-18-012100 · doc4.xml · nonDerivative · entry 6 Bolzon Bradley J PhD · CIK 0001354345 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 34,977 F4 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Versant Affiliates Fund V, L.P. ("VAF V"). F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.00 to $51.61 per share, inclusive. The reporting person undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F5 · ownership.nature: These securities are held of record by VAF V. VV V is the sole general partner of VAF V and may be deemed to have voting and investment power over the securities held by VAF V and as a result may be deemed to have beneficial ownership over such securities. The Reporting Person is a managing director of VV V and may be deemed to indirectly beneficially own the securities through his interest in VV V. The Reporting Person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, if any. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.